Navamedic ASA (OSL:NAVA)
Norway
· Delayed Price · Currency is NOK 19.00
-0.30 (-1.55%)
Apr 29, 2026, 4:17 PM CET
Navamedic ASA Revenue
Navamedic ASA had revenue of 137.90M NOK in the quarter ending March 31, 2026, with 4.45% growth. This brings the company's revenue in the last twelve months to 571.24M, up 5.28% year-over-year. In the year 2025, Navamedic ASA had annual revenue of 565.36M with 6.38% growth.
Revenue (ttm)
571.24M
Revenue Growth
+5.28%
P/S Ratio
0.81
Revenue / Employee
15.03M
Employees
38
Market Cap
462.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 565.36M | 33.92M | 6.38% |
| Dec 31, 2024 | 531.44M | 19.44M | 3.80% |
| Dec 31, 2023 | 512.00M | 129.86M | 33.98% |
| Dec 31, 2022 | 382.14M | 103.70M | 37.24% |
| Dec 31, 2021 | 278.44M | 68.56M | 32.67% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medistim ASA | 699.77M |
| Circio Holding ASA | 123.00K |
| Nordhealth AS | 601.75M |
| Photocure ASA | 532.58M |
| Vistin Pharma ASA | 449.47M |
| Omda AS | 495.69M |
| Lytix Biopharma ASA | 377.00K |
| Gentian Diagnostics ASA | 176.50M |
Navamedic ASA News
- 7 days ago - Navamedic ASA (OSL:NAVA) Q1 2026 Earnings Report Preview: What To Expect - GuruFocus
- 2 months ago - Navamedic ASA (OSL:NAVA) Q4 2025 Earnings Report Preview: What To Look For - GuruFocus
- 11 months ago - Navamedic ASA Transcript: M&A Announcement - Transcripts